Eldon Scott Priestley

This inventor holds 24 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 15 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bristol-Myers Squibb Compnay, Universitéde Montreal. Active years: 2004-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eldon Scott Priestley. Retrieved from https://idiyas.com/inventor/eldon-scott-priestley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 15 (Patent Applications = 13)

Average Co-Inventor Count = 5.9

ph-index = 5

Forward Citations = 74(Granted Patents)

Location History:

Hockessin, DE (US) (2004)
Yardley, PA (US) (2008 - 2024)
Hopewell, NJ (US) (2022 - 2024)

Company Filing History:

24 out of 3,742

Bristol-Myers Squibb Compnay

patents

7 out of 189

Universitéde Montreal

patents

where one patent can have more than one assignee

Years Active: 2004-2026

Loading Chart...

Areas of Expertise:

PAR4 Inhibitors

Anticoagulants

Heteroaryl Compounds

Imidazothiadiazole

Bicyclic Compounds

Nitrogen Containing Compounds

Factor VIIa Inhibitors

Benzamide Derivatives

Phenylglycinamide

Macrocyclic Compounds

Bicyclic Lactams

Hepatitis C Treatment

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12528827 - Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors (2026-01-20),

2. 12084452 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2024-09-10),

3. 12060347 - Bicyclic heteroaryl substituted compounds (2024-08-13),

4. 12037324 - Biarylmethyl heterocycles (2024-07-16),

5. 11932658 - Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors (2024-03-19),

6. RE49700 - Substituted nitrogen containing compounds (2023-10-17),

7. 11407733 - Biarylmethyl heterocycles (2022-08-09),

8. 10822343 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation (2020-11-03),

9. 10815224 - Monocyclic heteroaryl substituted compounds (2020-10-27),

10. 10730868 - Bicyclic heteroaryl substituted compounds (2020-08-04),

11. 10723723 - Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors (2020-07-28),

12. 10501449 - Substituted nitrogen containing compounds (2019-12-10),

13. 10428077 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation (2019-10-01),

14. 10047103 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2018-08-14),

15. 9688695 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2017-06-27),

Title: **Eldon Scott Priestley: Innovator in Pharmaceutical Chemistry**

Introduction

Eldon Scott Priestley is a prominent inventor based in Yardley, PA, known for his significant contributions to pharmaceutical chemistry. With a remarkable portfolio of 23 patents, Priestley has established himself as a key figure in the development of novel therapeutic compounds aimed at treating various medical conditions.

Latest Patents

Among his latest patents is an innovative approach to inhibiting platelet aggregation. One patent focuses on imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors. This invention details thiazole compounds designed to serve as effective medicaments for preventing thromboembolic disorders. Additionally, he has developed bicyclic heteroaryl substituted compounds, which include methods of usage as PAR4 inhibitors. These compounds are poised to play an essential role in treating thromboembolic disorders or providing primary prophylaxis against them.

Career Highlights

Priestley’s career features prominent affiliations with leading organizations in the pharmaceutical sector. Notably, he has worked with Bristol-Myers Squibb Company, where he contributed to the development of groundbreaking medical technologies. His time at universities also showcases his commitment to research and innovation, including his association with Université de Montréal.

Collaborations

Collaboration has been a cornerstone of Priestley's career. He has worked alongside esteemed colleagues such as Xiaojun Zhang and Jeremy M. Richter. Their combined expertise has fostered advancements in the understanding and application of compounds targeting platelet aggregation.

Conclusion

Eldon Scott Priestley’s contributions to pharmaceutical innovations demonstrate the vital role of inventors in advancing medical science. With his extensive patent portfolio, he continues to pave the way for new treatments that can significantly impact patient care, particularly in the management of thromboembolic disorders.

Profile summary based on public USPTO records.